Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Optimizing liver health before and after gene therapy for hemophilia A.

Blood advances·2024
Same author

Edson Lee Forker.

Hepatology (Baltimore, Md.)·2023
Same author

Loss of alcohol dehydrogenase 1B in cancer-associated fibroblasts: contribution to the increase of tumor-promoting IL-6 in colon cancer.

British journal of cancer·2022
Same author

Transcriptional Profiling in Experimental Visceral Leishmaniasis Reveals a Broad Splenic Inflammatory Environment that Conditions Macrophages toward a Disease-Promoting Phenotype.

PLoS pathogens·2017
Same author

Transcriptomics of Environmental Enrichment Reveals a Role for Retinoic Acid Signaling in Addiction.

Frontiers in molecular neuroscience·2016
Same author

Convergent transcriptomics and proteomics of environmental enrichment and cocaine identifies novel therapeutic strategies for addiction.

Neuroscience·2016

Related Experiment Video

Updated: Jan 11, 2026

Implementation of Non-invasive Point of Care Transient Elastography for Evaluation of Liver Disease in Pediatric Populations with Cystic Fibrosis
05:56

Implementation of Non-invasive Point of Care Transient Elastography for Evaluation of Liver Disease in Pediatric Populations with Cystic Fibrosis

Published on: August 29, 2025

419

Noninvasive tests for liver fibrosis.

Bruce A Luxon1

  • 1Division of Gastroenterology and Hepatology, University of Iowa Hospitals and Clinics, Iowa City 52242, USA. bruce-luxon@uiowa.edu

Postgraduate Medicine
|November 30, 2006
PubMed
Summary

Developing reliable fibrosis markers for liver diseases like hepatitis C and NASH remains a challenge. Current tests show promise in distinguishing fibrosis stages but lack universal clinical validation, meaning liver biopsy is still the gold standard.

Area of Science:

  • Hepatology
  • Biomarker Discovery

Background:

  • Non-invasive markers for liver fibrosis are needed for common hepatic diseases such as hepatitis C and non-alcoholic steatohepatitis (NASH).
  • Existing research has not yet yielded clinically validated fibrosis markers or scoring systems.
  • The primary clinical utility of such markers would be to differentiate between minimal and advanced fibrosis or cirrhosis.

Purpose of the Study:

  • To review the current status and clinical utility of fibrosis markers and scoring systems for liver diseases.
  • To assess the potential of existing marker panels in distinguishing fibrosis stages.
  • To highlight the need for further validation and clinical acceptance of non-invasive liver fibrosis assessment tools.

Main Methods:

  • Review of existing research studies on liver fibrosis markers.

More Related Videos

Author Spotlight: Advancing Hepatic Fibrosis Diagnosis Using Magnetic Resonance Elastography and AI
06:09

Author Spotlight: Advancing Hepatic Fibrosis Diagnosis Using Magnetic Resonance Elastography and AI

Published on: July 21, 2023

1.8K
Measurement of Liver Stiffness Using Atomic Force Microscopy Coupled with Polarization Microscopy
10:10

Measurement of Liver Stiffness Using Atomic Force Microscopy Coupled with Polarization Microscopy

Published on: July 20, 2022

4.5K

Related Experiment Videos

Last Updated: Jan 11, 2026

Implementation of Non-invasive Point of Care Transient Elastography for Evaluation of Liver Disease in Pediatric Populations with Cystic Fibrosis
05:56

Implementation of Non-invasive Point of Care Transient Elastography for Evaluation of Liver Disease in Pediatric Populations with Cystic Fibrosis

Published on: August 29, 2025

419
Author Spotlight: Advancing Hepatic Fibrosis Diagnosis Using Magnetic Resonance Elastography and AI
06:09

Author Spotlight: Advancing Hepatic Fibrosis Diagnosis Using Magnetic Resonance Elastography and AI

Published on: July 21, 2023

1.8K
Measurement of Liver Stiffness Using Atomic Force Microscopy Coupled with Polarization Microscopy
10:10

Measurement of Liver Stiffness Using Atomic Force Microscopy Coupled with Polarization Microscopy

Published on: July 20, 2022

4.5K
  • Analysis of the utility of various marker panels in assessing fibrosis severity.
  • Comparison of non-invasive markers with the current gold standard, liver biopsy.

    • Main Results:

    • Several panels of biomarkers have demonstrated potential in distinguishing between minimal and advanced liver fibrosis.
    • Despite promising results in research settings, no non-invasive marker or scoring system has achieved widespread clinical validation for all hepatic diseases.
    • Liver biopsy remains the definitive diagnostic standard for assessing liver fibrosis in clinical practice.

    Conclusions:

    • There is a critical need for validated, clinically useful non-invasive markers or scoring systems for liver fibrosis.
    • Current non-invasive markers show promise, particularly for differentiating fibrosis stages, but require further validation.
    • Liver biopsy continues to be the gold standard for liver fibrosis assessment until non-invasive methods are clinically accepted.